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Abstract 
The care of people with motor neurone disease / amyotrophic lateral sclerosis is often complex and 
involves a wide multidisciplinary team approach. The National Institute for Health and Care 
Excellence (NICE) in the UK have produced an evidence based guideline for the management of 
patients. This has made recommendations, based on clear evidence or consensus discussion. The 
evidence is often limited and areas for further research are suggested. 
 
 
Introduction 
The care of people with motor neurone disease (MND / amyotrophic lateral sclerosis (ALS)) is 
complex. Individuals who are affected experience multiple symptoms and issues that may change 
quickly, with a pattern of deterioration that can be difficult to predict. Guidelines for the care of 
people have been produced  W both in Europe with the European Federation of Neurological Societies 
Guideline on ALS (1) and in the USA the Practice Parameter from the American Association of 
Neurology (2).  Within the UK the National Institute for Health and Care Excellence (NICE) had 
published guidelines on the use of riluzole for MND (3) and the use of non-invasive ventilation (NIV) 
(4) but there was no overall guideline on the clinical care of people with MND. It was felt that the 
care of people with MND across the UK was very variable. Although there are multidisciplinary team 
clinic and networks providing co-ordinated multidisiciplinary care  many patients are isolated and 
their care is less than ideal.  Thus a a guideline on the care and management of MND was developed 
in early 2016 to consider the clinical and cost effectiveness of the care of people with MND from 
diagnosis to death(5) .  The earlierguideline on NIV was updated and incorporated within this new 
Guideline. . The Recommendations shown below reflect those in the Guideline, and fuller versions 
are available in the main Guideline documents (5). 
 
 
Methods of developing the Guideline  
NICE commissioned the National Clinical Guideline Centre, based at the Royal College of Physicians, 
London to undertake the development of the guideline.  There is a rigorous process for all stages of 
guideline development as there is a requirement for recommendations to be based the assessment 
of the best available evidence.   
 An initial scoping exercise was undertaken using interested stakeholders including professionals and 
organisations representing people with MND. The scope defined the guideline population and 
specific areas that would be considered. There were 21 clinical questions in the guideline, each of 
which was addressed through a systematic review of the literature. The reviews were developed in 
accordance with the methods outlined in the NICE guidelines manual (6). This guideline included 
intervention (treatment) reviews, prognostic reviews, and qualitative reviews. A protocol was 
formulated for each clinical question indicating the objective of the evidence review and stating, a-
priori, criteria of the studies to be included, what data would be extracted from the studies, and how 
the data would be analysed. For example, for prognostic reviews, studies were only included if the 
risk factors pre-specified by the Guideline Development Group (GDG) were adjusted for each other 
using multivariate analysis.  Studies not meeting this requirement were not included.  
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A comprehensive literature search was undertaken for each question using MEDLINE, Embase, and 
The Cochrane Library. Additional subject specific databases (CINAHL and PsycINFO) were used for 
some questions.  An initial search of abstracts identified papers judged relevant to the review and 
full text of these were then subject to a definitive assessment.  For some questions no published 
evidence was found. 
Once the studies to be included were determined their data was extracted and, where possible, 
evidence was synthesised. For intervention and prognostic reviews, meta-analyses were conducted 
using Review Manager (RevMan) 5 software. Dichotomous outcomes in intervention reviews, such 
as mortality, were meta-analysed via risk ratios (relative risk). For continuous outcomes, such as 
quality of life, results were meta-analysed using weighted mean differences. For data synthesis in 
prognostic factor reviews the odds ratios, risk ratios or hazard ratios for the effect of the pre-
specified prognostic factors were extracted from the studies. Qualitative reviews were synthesised 
by thematic analysis, identifying sub-themes from the included papers and linking them to a generic 
theme and allowing a summary evidence table of generic themes and underpinning sub-themes to 
be produced.  
Where possible the quality of the evidence was assessed using Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) methodology (7). For the intervention questions, 
overall quality assessments were made for each outcome.  This included an appraisal of the risk of 
bias, indirectness (relevancy to the clinical question) and imprecision for each outcome in each 
included study. It also required a judgement of  “ŝŶĐŽŶƐŝƐƚĞŶĐǇ ? ?ƚŚĞŚĞƚĞƌŽŐĞŶĞŝƚǇŽĨeffect 
estimates between studies, and the possibility of publication bias. The quality rating for each 
outcome was determined to be high, moderate, low, or very low. A modified GRADE methodology 
was utilised for prognostic studies with the risk of bias rating assigned to each study for each 
combination of risk factor/outcome.  For both intervention and prognostic reviews, randomised 
controlled trial (RCTs) began at high quality and were downgraded whilst observational studies 
began at low quality and downgraded from there. Observational studies could be upgraded for 
quality if the evidence presented determined this. In terms of qualitative reviews, the 
methodological quality of each study was assessed using an NCGC-modified NICE checklist and the 
quality of the evidence was assessed by a modified GRADE approach for each outcome, taking  into 
account the applicability and theme saturation/sufficiency of the evidence. The evidence was graded 
 ‘ĂƉƉůŝĐĂďůĞ ?ŝĨƚŚĞĞǀŝĚĞŶĐĞǁĂƐĚŝƌĞĐƚůǇĂƉƉůŝĐĂďůĞƚŽƚŚĞƋƵĞƐƚŝŽŶ ?ĂŶĚŐƌĂĚĞĚƉĂƌƚŝĂůůǇĂƉƉůŝĐĂďůĞŝĨ
it was related but not sufficiently. 
The multidisciplinary Guideline Development Group (GDG), including 2 neurologists, 2 palliative care 
consultants two respiratory consultants, physiotherapist, occupational therapist, community 
matron, nurse specialist, general practitioner, speech and language therapist,  patient and carer 
representatives and co-opted neuro-psychologist, dietitian and social worker, made 
recommendations from the highest quality evidence that was found. In the absence of evidence 
expert opinion recommendations were made by consensus. 
For all questions the evidence for cost-effectiveness was considered. The health economist 
identified potentially relevant studies and reviewed, critically appraised and extracted key 
information from them, as described for the reviews above. NICE has set out principles to be used in 
these assessments and an intervention is considered to be cost-effective if the intervention 
dominates other strategies (is less costly in the use of resources and more clinically effective) or the 
intervention costs less than £20,000/ QALY compared to the next best strategy (6). When no 
relevant studies were found the GDG made a qualitative judgment based on the expected 
differences in resource use together with the clinical review of effectiveness. 
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Reviews were undertaken looking at information, prognostic factors, organisation of care, 
psychosocial support, end of life care, symptom management, nutrition, communication, respiratory 
impairment and non-invasive ventilation. 
The Recommendations shown below reflect those in the Guideline, and fuller versions are available 
in the main Guideline documents (5). The recommendations vary in their strength, taking into 
account the benefits and harms of an intervention and the underpinning evidence. Strong 
ƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐĂƌĞƐƚĂƚĞĚĂƐ “ŽĨĨĞƌ ?ǁŚĞŶŝƚŝƐĨĞůƚƚŚĂƚĨŽƌƚŚĞŵĂũŽƌŝƚǇŽĨƉĂƚŝents the 
ŝŶƚĞƌǀĞŶƚŝŽŶǁŝůůĚŽŵŽƌĞŐŽŽĚƚŚĂŶŚĂƌŵĂŶĚĂƌĞĐŽƐƚĞĨĨĞĐƚŝǀĞ ?ĂŶĚ “ĐŽŶƐŝĚĞƌ ?ŝƐƵƐĞĚǁŚĞŶƚŚĞ
intervention is felt to do more good than harm and is cost effective but other options may be 
similarly cost effective (6). In this paper the strength of the recommendation is not given, but further 
information and the full recommendations are available within the main Guidleine document 
(5)Recommendations 
Recognition and referral  
MND is a rare disease and as symptoms may be vague initially the diagnosis is often delayed. 
Qualitative studies, of medium quality, were reviewed and showed that there were many reasons 
for delay in diagnosis: patients often did not perceive the physical changes as significant and did not 
ask for help, when they did present to health care professionals the significance of the symptoms 
was not recognised and a variety of medical specialities could become involved as the wider 
significance of symptoms was not recognised, such as referral for leg weakness to rheumatology or 
orthopaedics rather than neurology (8,9,10).  
Recommendations 
y A protocol and pathway for referral should be available in all healthcare 
regions ) 
y Awareness of possible symptoms should be encouraged  
y If MND is suspected a referral should be made without delay  
y Information should be provided for patient and family at all stages 
 
Information and support at diagnosis  
As MND is rare the General Practitioner and other health and social care professionals may have 
little understanding and knowledge of the condition, but patients and families may have many 
concerns they wish to discuss. There is a need for careful and considered communication, with 
professionals who are able to respond to patient and family concerns (9, 11, 12).  Qualitative studies 
were considered and were of moderate quality and were evaluated together with the GDG 
experiences and knowledge when formulating the recommendations. 
x RecommendationsThe diagnosis of MND should be given by a consultant 
neurologist with     
knowledge and expertise in MND  
x It is important to ensure: 
y People are asked about their wishes for information and involvement of 
family / carers 
y Information on MND is provided as they wish  
y A single point of contact for the MND Multidisciplinary Team (MDT) 
should be available 
y Follow up appointment with a MDT member within 4 weeks  
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y A referral for social care should be made   
y If there are social care needs 
y To ensure ĐĂƌĞƌƐĂƌĞĂǁĂƌĞŽĨĂƌĞƌ ?ƐAssessment, and 
assessments are made financially and for care 
 
Organisation of care  
A person with MND has diverse and complex symptoms, necessitating the involvement of a variety 
of different specialists and services.  Moreover the disease progression varies greatly and there may 
be rapid change, with different symptoms adding to the complexity.  The GRADE review identified 
several papers of low or very low quality, largely because they were cohort studies and at risk of 
bias. The evidence was overall in favour of a co-ordinated team approach that appeared to increase 
survival, the use of riluzole and NIV (13, 14, 15, 16). The GDG concluded that the evidence 
demonstrated that a clinic based MDT with involvement of professionals, who could see patients at 
home, was both clinically and cost effective.  The GDG acknowledged other models of care 
organisation and recommended further research establishing whether benefits were maintained in 
other care models, such as a network based team. 
A review was also undertaken looking at the optimum frequency of assessment. No relevant 
literature was found and the GDG agreed on discussion that assessment every 2 to 3 months was 
appropriate, but more or less frequent review may be needed according to patient need.   
Recommendations 
y Co-ordinated care should be provided from a clinic based MND  multidisciplinary team  
 
y Based in hospital or community 
y Including health and social care professionals 
y With expertise in MND 
y Staff able to see people at home 
Ensuring communication to all health and social care professionals / 
Family / carers  
y  The skills of the multidisciplinary membership would include:  
y Neurologist 
y Specialist MND nurse 
y Dietitian 
y Physiotherapist 
y Occupational therapist 
y Respiratory healthcare professional 
y Speech and language therapist 
y Palliative care expertise  W may be one of the team members. Referral to 
specialist palliative care should be considered if there are complex needs 
 
y Co-ordinated assessments should be undertaken every 2-3 months according to the 
ƉĞƌƐŽŶ ?Ɛneeds and they could be seen earlier if there are changes in condition. If person cannot 
attend clinic care should be facilitated within the community. It is important to ensure all are 
informed of key decisions, with close liaison with General Practitioner.  
y The multidisciplinary team should assess, manage and review  
y Weight, nutritional intake, feeding, swallowing 
y Muscle problems  Wweakness , stiffness, cramps 
y Physical function 
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y Saliva problems  W drooling, thick saliva 
y Speech and communication 
y Cough effectiveness 
y Respiratory function 
 
Psychological care  
Psychological distress is an understandable response to the diagnosis of MND and progressive 
deterioration. EŽZd ?ƐŽƌĐŽŚŽƌƚƐƚƵĚŝĞƐǁĞƌĞŝĚĞŶƚŝĨŝĞĚ ?ůĂƌŐĞƋƵĂůŝƚĂƚŝǀĞůŝƚĞƌĂƚƵƌĞǁĂƐƌĞǀŝĞǁĞĚ
consisting of a number of high and moderate quality studies. The main themes that were derived 
from the evidence were: 
x Coping with the diagnosis 
Reactions to the diagnosis, making sense of the diagnosis and support following diagnosis 
x Understanding the disease 
Information seeking behaviour, sources of information and filtering of information 
x Acceptance 
Accepting the disease, coping and gaining control, finding meaning in life 
x Coping with a changed life 
DĂŝŶƚĂŝŶŝŶŐĂŶĚĐŽƉŝŶŐǁŝƚŚ “ŶŽƌŵĂůŝƚǇ ? ?ŚŽƉĞ ?ůŝǀŝŶŐĨŽƌƚŚĞŵŽŵĞŶƚĂŶĚůŽŽŬŝŶŐƚŽƚŚĞ
future 
x Changes in relationships 
Changes in identity and role, reduction in intimacy and the importance of touch (11, 12, 17) 
 
The evidence suggested that the psychological support provided needs to adapt through the disease 
course and regular assessment of psychological needs was important (17).  Informal support may 
often be helpful but referral for formal psychological assessment and management may be 
necessary. 
 
Recommendations 
y The MDT assessment should include discussion of the psychological / 
emotional impact of MND 
y Information on support should be offered to the person with MND and their 
family / carer   
y Social care should be discussed with experienced social care worker  W 
considering the need for personal care (with continuity of carers), finances, 
enabling social activities, hobbies and social media and respite care.  
 
 
Social care  
The diagnosis and management of MND takes place within health services and in the UK social care 
is provided by local authorities, who have a duty to assess their needs and those of their carers. As 
MND causes many different issues there is overlap with other areas of care. A review was 
undertaken to consider the social care support needs of patients and their families. Six qualitative 
studies were analysed and were felt to be of moderate or high quality and two main themes were 
identified - social care needs and the delivery of social care. The GDG concluded that regular 
assessment of social care needs was important, as the situation was continually changing. There was 
a need to ensure that care teams were aware of the specific issues of MND and the individuality of 
the issues patients faced. There was also a need to ensure continuity of care, so that carers providing 
7 
 
personal care were aware of the patient ?s specific needs and could provide effective care (12, 18, 19, 
20).   
Recommendations 
x A social care practitioner with knowledge of MND or rapidly progressive complex disabilities 
should discuss the needs and support information and access to personal care, equipment, 
financial support, support to engage in work, social activities and hobbies and respite care X 
x As MND progresses people may develop communication problems and have difficulty 
assessing support or services, such as accessing a call centre. It is important to ensure 
people are given different ways of getting in touch with support or services, with a 
designated contact if possible.  
 
Planning for end of life care  
 
MND is a life shortening illness with an average survival of 2 to 3 years following symptom onset, 
although 25% of individuals survive 5 years and 10% are alive at 10 years. A review was undertaken 
into the most appropriate ways of communicating and supporting people with MND and their 
families to help them anticipate and prepare for the end of life. 
Nine qualitative studies were analysed thematically and the evidence was mainly assessed as being 
of moderate or high quality. The key themes that emerged were: a need for information (what 
happens at the end of life), the importance of choice and control (through advance care planning) 
and the need for specific support (timely involvement of specialist palliative care) (17, 19, 21).  
Recommendations 
o All professionals should be open to discuss end of life care whenever the person asks and 
provide advice on 
y The discussion of their preferences and concerns about care at the end of life  
at trigger points such as diagnosis, interventions, respiratory function changes  
(Strong recommendation) 
y Support and advice on advance care planning  W including what may   
 happen and the consideration of advance care plans  
y Anticipatory medication at home  
y Specialist palliative care involvement 
y dŚĞƉĞƌƐŽŶ ?ƐǁŝƐŚĞƐ 
x Place of care    
y Place of death 
y What to happen if deterioration / other illness 
y As end of life approaches 
y Provision of additional support so family are able to reduce 
responsibility and spend time with the person 
y Ensure prompt access to  
y Communication aid to allow communication 
y Specialist palliative care 
y Equipment  - syringe driver, beds, commodes, hoist 
y Bereavement care for families / carers 
 
Provision of equipment to aid activities of daily living and mobility  
MND leads to significant physical disabilities, many of which require aids and adaptions to enable 
the person with MND to continue to function and undertake activities of daily living. These changes 
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are usually progressive over time. A review was undertaken of the equipment needs of people with 
MND and two qualitative studies of moderate or acceptable quality were found which considered 
the devices most used by people with MND and the level of satisfaction with this equipment (22, 
23). 
The recommendations were based on the evidence and the discussions of the GDG.  There were 
concerns that any equipment should be provided in a timely fashion and, as the disease was 
progressive, equipment should be adaptable to cope with further changes and this would help 
maintain quality of life and reduce the risk of adverse events such as falls and hospital admission.  
Co-ordination of the assessment and provision of all equipment was felt to be very important, 
including ensuring equipment was suitable for any adaptions to the environment and housing. 
Recommendations 
y Physiotherapy and occupational therapy assessments should be 
 undertaken   with regular review   
y Activities of daily living, mobility and prevention of falls, the home 
 environment and adaptation and assistive technology  W environmental 
 control  W should undertaken   
y Equipment should be provided without delay to allow maximise 
daily living  and independence   
y Equipment  should be able to change as deterioration occurs and be 
integrated with other aids  W eg AAC devices  
 
Nutrition  
Nutritional issues usually occur in MND, due to problems with feeding, and swallowing. A review was 
undertaken exploring the clinically and cost effective methods of maintaining nutritional intake and 
managing weight for whom a gastrostomy is not possible or appropriate.  Two studies were found, 
both of very low quality. The GDG made consensus recommendations having found little evidence 
supporting the use of any supplement feeding regimes (24).  It was felt important that weight was 
maintained and weights should be checked regularly. Quality of life is often related with fluid and 
nutritional intake and it was felt that enrichment of food and careful consideration of feeding and 
nutrition, including palatability and psychological issues were important. 
 
A further review considered the most appropriate timing for a gastrostomy tube placement. No 
literature was found and the GDG agreed by consensus.  It was felt that regular review and 
discussion of both nutritional and respiratory aspects was essential and there should be regular and 
careful discussion of the benefits and problems of gastrostomy placement with the person with 
MND and their family.  If a person with MND declined gastrostomy placement there should be 
discussion of the risks of late placement or no placement.  For patients with frontotemporal 
dementia a careful assessment of whether the person could cope and accept a gastrostomy was 
important, in collaboration with the family, carers and MDT. 
Recommendations 
y From diagnosis assess weight , nutrition and swallowing 
y Assess ability to eat and drink 
y Aids to help plate to mouth 
y Food / drink preparation 
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y Advice on positioning / seating / posture 
y Coping with social situations 
y If there are suspected swallowing problems ensure a swallowing assessment  
y Discuss gastrostomy early and regularly  
y If gastrostomy is needed this should be placed without delay  
 
 
Communication 
Speech problems are common in MND and articulation and voice quality may be affected.  Moreover 
upper limb weakness may reduce the ability to use technology.  Speech loss affects social 
relationships and engagement with health and social care. Augmentative and alternative 
communication (AAC) is highly individualised and involves the use of gesture, symbols, boards (low 
technology) and more complex computer based (high technology) systems. No studies were 
identified in this area and consensus was used by the GDG to make recommendations.  It was felt 
that enabling people with MND to communicate was very important for quality of life and often for 
survival, being able to call for assistance, as well as to maintain the person in their role in society and 
at work. Different forms of AAC may be needed and there was the need to be able to respond to 
changes in ability. There is a need for careful assessment, in collaboration with the person with 
MND, and ensuring that the person with MND, their family and carers and the professional carers 
are all aware of the use and have been trained in their use. 
Recommendations 
y Assess needs for communication, including face to face, telephone / 
email /  social media  
y Provide equipment and ensure it is integrated with other aids 
y Low level  - alphabet board, picture board 
y High level  W PC / Tablet based 
y Refer to specialised services if there are complex needs 
 
Muscle problems  
A review was undertaken for the pharmacological and non-pharmacological management of muscle 
symptoms (e.g. cramps, spasticity and weakness).  
For pharmacological interventions one review for muscle cramps and two other papers for 
functional disability and muscle strength were considered but were of low or very low quality. The 
GDG therefore made consensus recommendations for pharmacological treatment based on clinical 
experience. For cramps quinine was felt to be the standard clinical practice and other medication 
were to be second line use. For muscle stiffness pharmacological medication  W as in the 
recommendations below  W should be used. Careful titration of medication, to the maximum 
tolerated dose, should be undertaken for each individual. 
For non-pharmacological treatments physical therapy was considered in 2 studies of low or very low 
quality. There was some evidence of benefit of resistance exercise and range of movement exercise 
for muscle cramps, weakness and stiffness. It was also agreed that passive movement exercise for 
patients who have very limited movement may be beneficial.  One study considered transcranial 
magnetic stimulation (TMS) but this showed no clinical benefit. 
Recommendations 
10 
 
 Cramps 
x First line Quinine 
x Second line Baclofen, Tizanidine, Dantrolene, Gabapentin 
x Ensure medication is appropriate  W eg swallowing issues 
x Review regularly for effectiveness / side effects 
 Muscle stiffness/ spacticity /increased tone  
x Consider Baclofen, Tizanidine, Dantrolene, Gabapentin 
x If not effective / tolerated/ contraindicated, consider referral to a 
specialist service for the treatment of severe spasticity  
 Use of physiotherapy 
x Aims 
o Maintain joint range of movement 
o Prevent contractures 
o Reduce stiffness and discomfort  
x Can be resistance / active-assisted / passive 
x Check to see if family / carers can assist in the programme 
x May need referral for orthotics 
 
 
Saliva management  
 
Swallowing problems may lead to difficulties with saliva, which may be watery or sticky.  Drooling 
and feelings of choking may occur and are both distressing and embarrassing for people with MND. 
A review was undertaken into the interventions for saliva management and identified only 2 studies 
relating to MND and 14 studies for indirect populations with similar problems of drooling due to 
reduced swallowing, which were considered as the GDG agreed that they were relevant (25, 26).  
The majority of studies were of low or very low quality, with only three studies of moderate quality. 
The recommendations were made from the evidence and GDG consensus.  
 
Recommendations 
x For drooling: 
o Advice on posture / diet / swallowing / oral care 
o Antimuscarinic medication trial - Glycopyrrolate / 
glycopyrronium bromide, Hyoscine hydrobromide  
o Injection of Botulinum toxin A into salivary glands 
x For thick saliva 
o Stop medication that may thicken saliva 
o Advice on diet / posture 
o Humidification / nebulisers/ carbocisteine may be helpful 
 
Cough effectiveness  
Effective cough allows clearance of secretions and reduces the risk of aspiration. People with MND 
often develop weak inspiratory and expiratory muscles that reduces cough strength and this 
increases the risk of respiratory tract infections that are a cause of morbidity and mortality. A review 
was undertaken of the clinical and cost effectiveness of cough augmentation techniques for people 
with MND who have an ineffective cough.  3 studies were identified, but all very of very low quality, 
due to risk of bias and imprecision. 
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As all these studies were of low quality the GDG made recommendations based on their experience 
to augment the evidence. There was no strong evidence that any cough augmentation technique 
was better than the others. However it was felt that techniques to augment cough were useful and 
should be attempted first. If the cough augmentation techniques were ineffective or inappropriate 
manual breath stacking and then assisted breath stacking and finally mechanical cough assistance 
devices should be considered.  
 
Recommendations  
y Cough augmentation techniques should be offered if the 
person   cannot  cough effectively  
y Breath stacking and / or manual assisted cough should be tried 
y If bulbar dysfunction / breath stacking ineffective 
o Assisted breath stacking  W using lung volume recruitment 
bag 
o Mechanical cough assist considered  
 Breath stacking ineffective 
 and /or  
 During respiratory infection  
 
Respiratory function   
Respiratory muscle weakness resulting in respiratory impairment is a major feature of MND. There 
was a previous Guideline 105 on the use of Non-invasive ventilation (NIV) in MND and many 
recommendations were updated and incorporated into this Guideline. Three new reviews were 
undertaken in areas not previously considered in Guideline 105 (3). 
A review was undertaken on the experience of discontinuation of NIV following a request for NIV 
discontinuation by a patient. Two qualitative studies were found and the themes that emerged 
were: concerns about planning and timing;  issues of where to undertake discontinuation and the 
avoidance of hospitalisation;  concerns about how decisions were made; practical concerns as to 
how to turn off the machine; the differences in professional understanding of the ethical and legal 
aspects regarding withdrawal of NIV; concerns about the NIV use at the end of life;  the emotional 
burden of these decisions and the involvement in discontinuation;  and the need for team 
involvement and support (27, 28). The GDG agreed that NIV was one method of managing breathless 
towards the end of life and that patients should be made aware of other ways of managing these 
symptoms, including medication.  It was felt that it was essential to have careful discussion before 
initiation so that people with MND should have a realistic understanding and expectation of NIV, as 
to its advantages and disadvantages, how it may help in managing symptoms and can be life 
prolonging but would not stop disease progression and how NIV may be withdrawn. 
A review was undertaken on the most appropriate management of discontinuation of NIV.  No 
studies were found and the GDG based their recommendations on their experience and the 
information from qualitative studies.  It was agreed that ongoing discussion regarding the benefits of 
NIV was essential and this would include discussions of discontinuation. There are ethical and legal 
issues to be considered and advance care planning iƐǀĞƌǇŝŵƉŽƌƚĂŶƚŝŶĞŶƐƵƌŝŶŐƉĂƚŝĞŶƚƐ ?ǁŝƐŚĞƐĂƌĞ
known.  As it is a rare event for many teams the wider team should be involved, with advice from 
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people with experience if necessary.  The GDG also noted the guidelines on the withdrawal of NIV in 
MND that were available (29). 
A review was undertaken of pharmacological treatments that could manage symptoms of 
breathlessness in MND but no studies were identified. The GDG, by consensus, agreed that opioids 
and benzodiazepines are recognised treatments for the management of these symptoms within 
palliative care. 
Recommendations 
y Assessment  of respiratory function should be undertaken regularly 
y Discussion of management of breathlessness   
y NIV has advantages and disadvantages 
y Dependency on NIV is possible 
y Options for treating infections 
y Support of how to cope if there is a distressing situation and 
deterioration 
y Effectiveness of medication in  helping breathlessness  W e.g. opioids 
y Psychological approaches and support  
y Discuss use of NIV regularly at appropriate times , sensitively   
y Soon after diagnosis of MND 
y When monitoring respiratory function 
y When respiratory function deteriorates 
y If person asks 
y Discussion should provide information on 
y Possible signs and symptoms of respiratory impairment 
y Role of monitoring and explanation of results 
y The use of NIV to relieve symptoms and may prolong life, 
but does not stop the underlying progression of MND 
y  Offer non-invasive ventilation   
y If there is likely to be a benefit for the person 
y Consider trial of NIV in people with severe bulbar problems or 
severe cognitive problems - if it is thought they would cope with NIV 
and this may help in hypoventilation or sleep-related problems   
y Opioids / benzodiazepines may be used to relieve breathlessness 
y  Before starting NIV there should be risk assessment by the MDT  
y Most appropriate ventilator and interface 
y Tolerance to NIV 
y Risk of ventilator failure 
y Power supply needed  - including need for battery back up 
y How easy for the person to reach a hospital for help 
y Risk of travelling abroad if they wish to do so 
y Need for humidification 
y Assessment of secretions / saliva management 
y Availability of help from carers 
y Starting NIV 
y Initial acclimatisation in the day 
y Start regular use at night 
y Increase slowly in use 
y Training for person and family and carers is essential 
y The actions to be taken in emergency situations should be discussed 
y Secretion management is essential 
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y Palliative care strategies should be in place  W e.g. use of opioids and 
pƌŽǀŝƐŝŽŶŽĨ “:ƵƐƚŝŶĐĂƐĞ ?ĂŶƚŝĐŝƉĂƚŽƌǇŵĞĚŝĐĂƚŝŽŶ 
y Stopping NIV 
y There needs to be careful consideration of the plan to stop NIV  
y Ensure there is support from professionals who have expertise in stopping 
ventilation, using palliative medication, supporting the person, family 
/carers / health and social care professionals and the legal and ethical 
aspects 
 
Cognitive assessment  
There is increasing evidence that over 50% of people with MND have changes in cognitive function, 
varying from subtle cognitive impairment to frank frontotemporal dementia (30).  These changes 
have implications for communication, decision making and the care they may need. A review was 
undertaken looking at the optimum frequency of assessing cognitive function. No studies were 
identified and so the GDG, with a co-opted expert in neuro-psychology, used informal consensus to 
make recommendations. It was felt that if cognitive change occurs it often occurs early in the 
disease progression and assessment at diagnosis would help to plan further care.  Ongoing enquiry 
of cognitive or behavioural change may be helpful.  The GDG identified that this was an important 
area for further research. 
x At diagnosis or if there is a concern about cognition or behaviour explore these 
areas with the person and their family 
x If necessary undertake a formal assessment 
x Assess for capacity and adjust care accordingly 
x dĂŝůŽƌĚŝƐĐƵƐƐŝŽŶƐƚŽƚŚĞƉĞƌƐŽŶ ?ƐŶĞĞĚƐ ?ƚĂŬŝŶŐŝŶƚŽĂĐĐŽƵŶƚƚŚĞŝƌ
communication ability, cognitive status and mental capacity 
 
Prognostic factors  
The progression of MND for any particular patient is very variable. However patients and families 
may often wish to have a clearer idea of prognosis, as this could enable them to make plans for their 
lives, as well as enabling professionals to deliver more anticipatory management. A review was 
undertaken looking at the most accurate prognostic tools for estimating survival in MND. One study 
had produced an ALS Prognostic Index (31).  A further 11 studies were found in a review of the risk 
factors that predict survival in MND. These varied in quality but in some there was serious 
imprecision and the quality of the evidence was rated at low or very low.  The main risk factors that 
emerged were:  ALS FRS scale, the higher at diagnosis, the longer survival; Forced vital capacity 
(FVC), higher values with longer survival; weight change at diagnosis, low weight at diagnosis, weight 
loss predicts shorter survival; older age at diagnosis predicted shorter survival; bulbar onset 
predicted shorter survival; longer time to diagnosis predicted longer survival. 
The GDG felt that prognostication would be helpful for people with MND, their carers and 
professionals. The GDG considered that further research in this area would be helpful to be able to 
offer patients a more individualised prognosis.  
Recommendations 
x When planning care take into account that these factors are associated with 
shorter survival if they are present at diagnosis 
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o Speech and swallowing problems 
o Weight loss 
o Poor respiratory function 
o Older age 
o Lower  Amyotrophic Lateral Sclerosis Functional Rating Scale (ALS FRS-R) 
o Shorter time from developing symptoms to the time of diagnosis 
o Cognitive change 
 
Discussion 
The development of this Guideline involved a close collaboration between the Guideline technical 
team and the professionals and carers within the Guideline Development Group.  The evidence 
found was rarely from randomised controlled trials and so cohort studies or qualitative studies were 
used  W further information on the searches are available from NICE (5).  Consequently many 
recommendations were made by consensus from within the GDG.  
The recommendations are similar to those in previous Guidelines (1, 2) although they do incorporate 
the updated evidence base since they have been written and published. There are still areas without 
evidence and the GDG have suggested research areas for consideration: 
x What is the impact of assessing cognitive and behaviour change in people with 
MND on clinical practice, the person, their family and carers, and does repeated 
assessment provide greater benefit than at a single point at the point of 
diagnosis? 
x Is the ALS prognostic Index an accurate predictor of survival in people with 
MND? 
x How is excessive drooling of saliva (sialorrhoea) managed in people with MND? 
x Does a high calorific diet prolong survival of people with MND if initiated 
following diagnosis or following initiation of feeding by gastrostomy? 
x What is the current pattern of use of augmentative and alternative 
communication by people with MND in England? 
 
The use of health economics assessment was considered for all the recommendations but there was 
little evidence for most reviews, except for the organisation of care.  The GDG agreed that an in-
depth economic assessment would be undertaken for the use of Multidisciplinary Team approach, as 
there was literature on the benefits of the approach (13, 14, 15, 16).  This showed that MDT care 
was cost effective, with an Incremental Cost-Effectiveness Ratio (ICER) of £26,672 / QALY (Quality-
adjusted Life-years).  This study is to be presented as a separate publication (32).  There were 
particular issues in calculating the cost effectiveness as the quality of life would appear to be 
undervalued, as the model used the EQ-5D scale, which is limited in assessing the quality of life in 
people with progressive disease as they reach the lowest level at an earlier stage of the disease 
progression and the quality of life may be adversely assessed. If a more sensitive assessment of 
quality of life had been used the effectiveness would seem to be greater and the ICER lower  W for 
instance when the model was rerun adding a small increase in quality of life the ICER reduced to 
£20,469/QALY. 
The aim of this Guideline is to improve the care of people with MND in England, Wales and Northern 
Ireland. However, it is hoped that they will be of interest to other areas and together with other 
guidelines help to improve care more widely. 
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